Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...

Saphnelo (Anifrolumab) is instrumental in addressing autoimmune conditions by targeting and inhibiting the type I interferon receptor. Since this receptor is frequently overactive in autoimmune ...